Mantle Cell Lymphoma (MCL) is a rare type of non-Hodgkin lymphoma (NHL), making up about 5–7% of all NHL cases. It affects B cells — white blood cells found in the outer edge of lymph nodes called the "mantle zone."
MCL is generally considered an aggressive cancer, though a small number of people have a slower-growing Show Full Answer
Mantle Cell Lymphoma (MCL) is a rare type of non-Hodgkin lymphoma (NHL), making up about 5–7% of all NHL cases. It affects B cells — white blood cells found in the outer edge of lymph nodes called the "mantle zone."
MCL is generally considered an aggressive cancer, though a small number of people have a slower-growing (indolent) form. Because symptoms often don't appear until later stages, most people are diagnosed at an advanced stage. There are two main subtypes of MCL:
- Classical MCL – the more common and aggressive form; the blastoid variant is the most aggressive
- Leukemic non-nodal MCL – slower-growing and generally associated with a better outlook
Treatment options can include:
- Chemoimmunotherapy (chemotherapy + immunotherapy)
- Targeted drug therapy (e.g., bortezomib)
- Stem cell transplant
- Radiation therapy
- Active surveillance (for slow-growing cases only) As for survival, the median overall survival ranges from 6 to nearly 10 years, with improving outcomes thanks to newer treatments like rituximab. Those diagnosed after 2000 have shown a median survival of over 11 years — a hopeful sign that research is making a real difference.
Always speak with your oncologist about what these statistics mean for your specific situation, as individual factors like stage, genetics, and overall health all play a role.
October 6
Join
Your Privacy Choices
